-transparent.png){kind=logo}
In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation. Partial remissions were observed in five patients (13%), with a median duration of 9 months (range, 7-15), and stable disease was observed in 17 patients (45%), with a median duration of 4 months (range, 2-11). The recorded side effects (CNS, cutaneous, gastrointestinal) were tolerable and transient and required drug discontinuation in only four patients. Serial determinations of serum hormone levels during aminoglutethimide treatment revealed a significant decrease in estradiol and an increase in gonadotropins, testosterone, and progesterone. No patients had adrenal insufficiency. In contrast, despite prolonged aminoglutethimide treatment and persisting hypoestrogenemia, both cortisol levels and adrenal responses to ACTH remained unaltered. It is concluded that aminoglutethimide alone is effective in the treatment of postmenopausal patients with breast cancer. Moreover, based on the present findings, a prospective randomized study is warranted to show that hydrocortisone supplementation appears to not be mandatory, either for increase in efficacy or for decrease in side effects of the treatment.
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
February 1989,
European journal of cancer & clinical oncology,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
August 1982,
Cancer research,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
January 1983,
European journal of cancer & clinical oncology,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
January 1986,
Breast cancer research and treatment,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
January 1985,
European journal of cancer & clinical oncology,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
October 1985,
British journal of cancer,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
January 1986,
Breast cancer research and treatment,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
January 1982,
Annals of internal medicine,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
November 1984,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
K Höffken, and
H Kempf, and
A A Miller, and
B Miller, and
C G Schmidt, and
P Faber, and
H K Kley
April 1984,
European journal of cancer & clinical oncology,
